“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: A-128 PREVALENCE OF HETEROZYGOUS TYPE 2N VON WILLEBRAND DISEASE MUTATIONS IN BELGIUM

€2.42

SKU: product-article-18561 Category: General

Description
Reviews (0)

Description

A-128 PREVALENCE OF HETEROZYGOUS TYPE 2N VON WILLEBRAND DISEASE MUTATIONS IN BELGIUM

Reviews

There are no reviews yet.

Be the first to review “Article: A-128 PREVALENCE OF HETEROZYGOUS TYPE 2N VON WILLEBRAND DISEASE MUTATIONS IN BELGIUM”

Top

Article: A-128 PREVALENCE OF HETEROZYGOUS TYPE 2N VON WILLEBRAND DISEASE MUTATIONS IN BELGIUM

Description

Reviews

Related products

Article: INTRODUCTION

Article: Highlights in gynaecological cancers

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma

Article: Highlights in urologic cancer